# Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)

> **NCT03031782** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 86 (actual)

## Conditions studied

- Juvenile Psoriatic Arthritis
- Enthesitis-related Arthritis

## Interventions

- **DRUG:** secukinumab
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT03031782
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-23
- **Primary completion:** 2020-10-07
- **Final completion:** 2020-11-09
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2022-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03031782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03031782, "Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03031782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*